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1. Introduction 
Estimates of the worldwide incidence and mortality from 27 cancers in 2008 have been 
prepared for 182 countries by the International Agency for Research on Cancer (Ferlay et al., 
2010). Overall, an estimated 12.7 million new cancer cases and 7.6 million cancer deaths 
occur in 2008, with 56% of new cancer cases and 63% of the cancer deaths occurring in the 
less developed regions of the world. The most commonly diagnosed cancers worldwide are 
lung (1.61 million, 12.7% of the total), breast (1.38 million, 10.9%) and colorectal cancers (1.23 
million, 9.7%). Cancer is neither rare anywhere in the world, nor mainly confined to high-
resource countries. Many cancer subjects die from cancer as a result of organ failure due to 
“metastasis” (Geiger & Peeper, 2009), thus indicating that medical control of tumor 
metastasis leads to a marked improvement in cancer prognosis. 
The acquisition of the metastatic phenotype is not simply the result of oncogene mutations, 
but instead is achieved through an interstitial stepwise selection process (Mueller & Fusenig, 
2004). The dissociation and migration of cancer cells, together with a breakdown of 
basement membranes between the parenchyme and stroma, are a prerequisite for tumor 
invasion. The next sequential events involved in cancer metastasis include the following: (i) 
penetration of cancer cells to adjacent vessels (i.e., intravasation); (ii) suppressed anoikis (i.e., 
suspension-induced apoptosis) of cancer cells in blood flow; and (iii) an extravascular 
migration and re-growth of metastatic cells in the secondary organ. For an establishment of 
anti-metastasis therapy, it is important to elucidate the basic mechanism(s) whereby tumor 
metastasis is achieved through a molecular event(s). 
Hepatocyte growth factor (HGF) was discovered and cloned as a potent mitogen of rat 
hepatocytes in a primary culture system (Nakamura et al., 1984, 1989; Nakamura, 1991). 
Beyond its name, HGF is now recognized as an essential organotrophic regulator in almost 
all tissues (Nakamura, 1991; Rubin et al., 1993; Zarnegar & Michalopoulos, 1995; Birchmeier 
& Gherardi, 1998; Nakamura & Mizuno, 2010). Actually, HGF induces mitogenic, motogenic 
www.intechopen.com
 Hydrodynamics – Advanced Topics 
 
120 
and morphogenic activities in various types of cells via its receptor, MET (Bottaro et al., 1991; 
Higuchi et al., 1992). HGF is required for organogenesis in an embryonic stage and for tissue 
repair in adulthood during various diseases (Nakamura, 1991; Birchmeier & Gherardi, 1998; 
Nakamura & Mizuno, 2010). Several lines of in vitro studies indicate that HGF stimulates 
scattering and migration of cancer cells (Matsumoto et al., 1994, 1996a; Nakamura et al., 
1997). In malignant tumors, HGF is expressed by stromal cells, such as fibroblasts, while 
MET is over-expressed by cancer cells, thus suggesting in the mid-1990s that a paracrine 
signal from HGF-producing stroma cells to carcinomas may cause malignant behaviors, 
such as invasion and metastasis (Matsumoto et al., 1996b). 
NK4 is an intra-molecular fragment of HGF, which is generated by a chemical cleavage of 
mature form HGF (Date et al., 1997; Nakamura et al., 2010). NK4 includes an N-terminal 
hairpin domain and 4-kringle domains (K1-K4) of HGF α-chain, which binds to MET. Thus, 
NK4 antagonizes HGF activities as a competitive inhibitor. Using NK4 as an HGF-
antagonist in rodents with malignant tumors, we have accumulated evidence showing that 
endogenous HGF-MET cascade is a key conductor for tumor metastasis, while inhibition of 
MET signals leads to the arrests of tumor growth. Unexpectedly, NK4 prohibits tumor 
angiogenesis through a MET-independent mechanism. This review focuses on the roles of 
HGF in cancer biology and pathology. We also emphasize the effectiveness of NK4 in 
experimental cancer models where NK4 is supplemented via a “hydrodynamics-based” 
gene therapy. 
2. Effects of HGF on intra-tumor cells during cancer progression 
In the mid-1980s, MET was identified as a mutated oncogene from carcinogen-induced 
osteosarcoma cells (MNNG-HOS) that transform NIH3T3 fibroblasts (Cooper et al., 1984). 
MET-encoding protein has a tyrosine kinase activity (Dean et al., 1985), suggesting that MET 
may be an orphan receptor of growth factors. In the early 1990s, MET-coding product was 
demonstrated to be a high-affinity receptor for HGF (Bottaro et al., 1991; Higuchi et al., 1992). 
Scatter factor (SF) stimulates tumor cell movement, as its name indicates, and is shown 
molecularly identical to HGF (Konishi et al., 1991; Weidner et al., 1991). HGF has several 
activities required for tumor cell invasion and metastasis, as described below. In this section, 
we summarize the direct effects of HGF on intra-tumor cells, including carcinoma, and on 
vascular and lymphatic cells prior to discussion of the contribution of HGF-MET cascades 
during tumor malignancy. 
2.1 Scattering and migration of tumor cells 
Initial events for the metastatic spread of tumors involve loss of cell-cell contact within the 
primary tumor mass. The integrity and morphology of epithelial tumor cell colonies are 
maintained by cell-cell contact mediated by cadherins and its associated intracellular catenin 
molecules. Cancer cells must lose their tight cell-to-cell contact by down-regulation of 
cadherin-cadherin complex during invasion into adjacent tissues. HGF induces scattering (i.e., 
dispersion of cluster cells into single cells) via an endocytosis of E-cadherin from cell surface to 
cytoplasma (Watabe et al., 1993; Miura et al., 2001). During cell migration, HGF activates the 
Ras-Rab5 pathway for endocytosis of cadherins (Kimura et al., 2006), which triggers nuclear 
localization of β-catenin, a transcription factor of genes responsible for cell motility (Hiscox & 
Jiang, 1999). Stimulation of an Rho small G protein cascade and activation of cdc42, rac and 
PAK by HGF leads to the disassembly of stress fiber or focal adhesions, while lamellipodia 
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formation and cell spreading are enhanced by HGF (Royal et al., 2000). These changes confer a 
down-stream mechanism of MET-mediated cancer invasion. 
2.2 Breakdown of basement membranes 
During cancer invasion, tumor cells must move across a basement membrane between 
epithelium and lamina propria (i.e., sub-epithelium). HGF stimulates motility in a biphasic 
process: cells spread rapidly and form focal adhesions, and then they disassemble these 
condensations, followed by increased cell locomotion. In the early phase (i.e., within a few 
minutes post-stimulation), HGF induces phosphorylation of focal adhesion kinase (FAK) 
together with a tight bridge between the extra-cellular matrix (ECM) and integrins of cancer 
cells (Matsumoto et al., 1994; Parr et al., 2001). In the later phase, HGF-stimulated cancer cells 
invade into matrix-based gels in vitro, or across basement membrane ECM in vivo 
(Nakamura et al., 1997). In this process, HGF up-regulates several types of matrix 
metalloproteinase (MMP), such as MMP-1, -2, and -9, through activation of Ets, a 
transcriptional factor of MMPs (Li et al., 1998; Nagakawa et al., 2000; Jiang et al., 2001). 
Considering that MMP-inhibitors diminish HGF-mediated migration, the induction of MMP 
through HGF-Ets cascade is essential for tumor invasion into adjacent normal tissues. 
2.3 Endothelial attachment and extravasation of cancer cells 
Needless to say, tumor angiogenesis as well as lymphatic vessel formation are important for 
delivery of cancer cells from the primary tumor to secondary organs. HGF enhances 
angiogenesis via induction of the proliferation and morphogenesis of endothelial cells (EC) 
(Bussolino et al., 1992; Nakamura et al., 1996). Actually, HGF supplementation leads to the 
enhancement of tumor angiogenesis in vivo (Laterra et al., 1997). Recent studies delineated 
the capacity of HGF to induce lymphatic morphogenesis (Kajiya et al., 2005; Saito et al., 
2006). Thus, HGF is considered to facilitate cancer metastasis via neo-induction of vascular 
or lymphatic vessel beds. HGF has a direct effect on EC for enhancing tight adhesion of 
tumor cells on endothelium via FAK phosphorylation (Kubota et al., 2009a). Furthermore, 
HGF decreases endothelial occludin, a cell-cell adhesion molecule (Jiang et al., 1999a). Under 
such a loss of EC-EC integrity, HGF decreases the trans-endothelial resistance of tumor 
vessels and enhances cancer invasion across an EC barrier (i.e., intravasation in primary 
tumors and extravasation in metastatic organs) (Fig. 1). 
2.4 Prevention of cancer cell anoikis 
Anoikis, also known as suspension-induced apoptosis, is a term used to describe 
programmed cell death (apoptosis) of epithelial cells induced by loss of matrix attachment. 
In addition to gaining functions of invasion and angiogenesis, cell resistance to anoikis also 
appears to play an important role in tumor progression and metastasis as tumor cells lose 
matrix attachment during metastasis. However, it is unknown how cancer cells escape from 
anoikis-like death during metastasis. It was demonstrated, in a non-adherent culture 
models, that HGF is a key molecule inhibiting suspension-induced anoikis, and this effect is 
mediated via a crosstalk that is, in turn, mediated by phosphatidyl-inositol 3-kinase (PI-3K) 
and extracellular signal-regulated kinase (ERK)-1/2 (Zeng et al., 2002; Kanayama et al., 2008). 
A recent report described that tetraspanin CD151-knockdown abolishes preventive effect of 
HGF on tumor anoikis (Franco et al., 2010). Thus, it is likely that cell surface tetraspanins are 
important for signaling complexes between MET and integrin-β4, a known amplifier of 
HGF-mediated cell survival. 
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Fig. 1. Various effect of HGF on cancer cells and endothelial cells (EC) during tumor 
progression. For example, sequential events during the lung metastasis of hepatic carcinoma 
are summarized as follows: (A) dissociation and scattering of hepatocellular cancer cells 
through an HGF-induced endocytosis of cadherins; (B) tumor migration into stromal areas 
across the basement membrane (BM) is mediated via MMP-dependent matrix degradation 
and Rho-dependent cell movement; (C) invasion of tumor cells into neighboring vessels (i.e., 
intravasation) where the tight junction between ECs is lost by HGF-MET signaling; (D) 
inhibition of tumor cell anoikisis by MET-AKT cascades during blood flow, and out-flux of 
tumor cells across vessel walls (i.e., extravasation); and (E) in the lung, HGF supports 
growth of metastatic nodules via providing vascular beds as an angiogenic factor. 
Overall, HGF is shown to take direct action on carcinoma cells: (i) cell spreading via an 
endocytosis of cadherins; (ii) enhancement of invasion across basement membranes via Rho-
dependent and MMP-dependent pathways; and (iii) anti-anoikis activity during blood 
circulation. Toward tumor vessels, HGF elicits vascular and lymphatic EC proliferation and 
branching angiogenesis, while intravasation and extravasation are achieved through HGF-
induced reduction of EC-EC integrity. These HGF-MET-mediated biological functions seem 
advantageous for invasion and metastasis of malignant tumors, including carcinoma and 
sarcoma (Fig. 1). 
[Note] Long-term administration of recombinant HGF does not elicit tumor formation in 
healthy animals, and this result supports a rationale of HGF supplement therapy for treating 
chronic organ diseases, such as liver cirrhosis, at least in cancer-free patients. 
3. Regulation of HGF production by cancer cells 
Several lines of histological evidence indicate that HGF is produced in stroma cells, such as 
fibroblasts, vascular EC and smooth muscle cells in tumor tissues. In contrast, MET is over-
expressed mainly by tumor cells, particular near invasive areas, implying a possible 
paracrine signal from HGF-producing stroma cells to MET-expressing carcinoma cells 
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(Matsumoto et al., 1996b). Herein, we will discuss the molecular basis whereby stromal HGF 
production is up-regulated by tumor cells during cancer invasion and metastasis. 
3.1 Stroma as a microenvironment to determine behaviors of tumors 
The important roles of stroma during tumor progression are demonstrated through several 
independent studies. Carcinoma-associated fibroblasts, but not normal fibroblasts, stimulate 
tumor progression of initiated non-tumorigenic epithelial cells both in an in vivo tissue 
recombination and in an in vitro co-culture system (Olumi et al., 1999). Transforming growth 
factor (TGF)-β signaling is critical for down-regulating HGF production (Matsumoto et al., 
1992). Of note, an inactivation of TGF-β type II receptor gene in stromal fibroblasts leads to 
the onset of epithelial growth and invasion (Bhowmick et al., 2004). In this process, 
activation of paracrine HGF is a key mechanism for stimulation of epithelial proliferation 
(Bhowmick et al., 2004). Thus, the suppression of HGF production by TGF-β seems to be 
important for an escape from cancer metastasis (Matsumoto & Nakamura, 2006).  
3.2 Regulation of HGF production in stroma by tumor cells 
As repeated, a major source of HGF in tumors is stromal cells (including fibroblasts, 
endothelium, macrophages and neutrophils) (Wislez et al., 2003; Matsumoto & Nakamura, 
2006; Grugan et al., 2010). Thus, how stromal HGF is up-regulated during tumor progression 
should be discussed. There is now ample evidence that numerous types of carcinoma cells 
secrete soluble factors that induce HGF production in stromal cells (i.e., HGF-inducers). For 
example, conditioned medium obtained from breast cancer cells enhances HGF production 
in fibroblasts, along with a raise in prostaglandin-E2 (Matsumoto-Taniura et al., 1999). Of 
note, suppression of prostaglandin-E2 production by indomethacin leads to down-
regulation of stromal HGF production and suppression of tumor migration in vitro 
(Matsumoto-Taniura et al., 1999), indicating that cancer-derived prostaglandins are 
important for up-regulating HGF in stromal cells (Matsumoto-Taniura et al., 1999; Pai et al., 
2003). Other carcinoma-derived HGF-inducers are interleukin-1β (IL-1β), basic fibroblast 
growth factor (b-FGF), platelet-derived growth factor (PDGF), and TGF-α (Hasina et al., 
1999; Matsumoto & Nakamura, 2003). These results indicate a crosstalk between carcinoma 
and stroma, mediated via a paracrine loop of HGF-inducers produced by carcinoma and 
HGF secreted from stroma cells, such as fibroblasts (Matsumoto et al., 1996a). 
3.3 Inflammation-mediated HGF up-regulation mechanism 
In addition to stromal fibroblasts, tumor-associated macrophages (TAM) are known to 
highly produce HGF during non-small lung cancer invasion (Wang et al., 2011). It is 
reported that TAM isolated from 98 primary lung cancer tissues show the higher production 
of HGF, along with the concomitant increases in urokinase-type plasmin activator (uPA), 
cyclooxygenase-2 (Cox2) and MMP-9 (Wang et al., 2011). Anti-MMP-9 antibody largely 
diminishes TAM-induced invasion, while Cox2 and uPA are critical for HGF production 
and activation, respectively, suggesting that Cox2-uPA-HGF-MMP cascades in TAM 
participate in non-small lung cancer invasion. Likewise, HGF production is enhanced by 
neutrophils infiltrating bronchiolo-alveolar subtype pulmonary adenocarcinoma (Wislez et 
al., 2003). 
Clinical studies demonstrate that serum levels of HGF are elevated in patients with 
recurrent malignant tumors (Wu et al., 1998; Osada et al., 2008), thus suggesting an 
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endocrine mechanism of the HGF delivery system. In this regard, it is known that peripheral 
blood monocytes produce HGF, contributing to the increase in blood HGF levels via an 
endocrine mechanism (Beppu et al., 2001). Overall, production of HGF by inflammatory cells 
is involved in carcinoma invasion and metastasis (i.e., local system), while peripheral blood 
monocytes seem to prevent tumor cell anoikis during metastasis, possibly by a release of 
HGF into blood (i.e., systemic system). 
4. Structure and activity of NK4 as HGF antagonist 
HGF is a stromal-derived paracrine factor that has stimulated cancer invasion at least in vitro 
(Matsumoto et al., 1994; Matsumoto et al., 1996a; Nakamura et al., 1997). Clinical studies 
suggest that the degree of serum HGF and Met expressions in cancer tissues appears to 
correlate with a given prognosis (Yoshinaga et al., 1993; Osada et al., 2008). Thus, it is 
hypothesized that in vivo inhibition of HGF-MET signaling may be a reasonable strategy to 
prohibit cancer metastasis. To test this hypothesis, we prepared NK4 as an intra-molecular 
fragment of HGF via a chemical digestive process (Date et al., 1997; Matsumoto et al., 1998). 
As expected, NK4 bounded to MET and inhibited HGF-MET coupling as a competitive 
inhibitor. An additional “unexpected” value was that NK4 inhibited tumor angiogenesis via 
a MET-independent pathway. This section focuses on the biological value of NK4 as an 
HGF-antagonist and as an angiogenesis inhibitor. 
4.1 Structure and anti-invasive function of NK4 
NK4 was initially purified as a fragment from elastase-digested samples of recombinant 
human HGF (Date et al., 1997). The N-terminal amino acid sequence of NK4 and of the 
remnant fragment, assumed to be composed of an HGF β-chain, revealed that NK4 is 
cleaved between the 478th valine and the 479th asparagine. The N-terminal amino acid 
sequence of NK4 revealed that the N-terminal structure of NK4 is the same as undigested 
HGF (i.e., 32nd pyroglutamate), indicating that NK4 is composed of the N-terminal 447 
amino acids of the α-chain of HGF and contains the N-terminal hairpin domain and four 
kringle domains (thus designated NK4) (Fig. 2A). The binding domains that are 
responsible for high-affinity binding to MET are the N-terminal hairpin and the first 
kringle domains in NK4 (and HGF). MET tyrosine phosphorylation occurs in A549 lung 
carcinoma within 10 minutes after HGF addition, while NK4 inhibits the HGF-mediated 
MET activation (Fig. 2B). Actually, NK4 functions as an HGF-antagonist: HGF induces 
invasion and migration of the gallbladder and bile duct carcinoma cells in ECM-based 
gels, while NK4 inhibits HGF-induced invasion in a dose-dependent manner (Fig. 2C) 
(Date et al., 1998). These anti-invasive effects of NK4 are seen in distinct types of cancer 
cells (Hiscox et al., 2000; Maehara et al., 2001; Parr et al., 2001), strengthening the common 
role of NK4 during cancer migration. 
4.2 Perlecan-dependent anti-angiogenic mechanism by NK4 
Vascular EC highly express MET, while HGF stimulates mitogenic and morphogenic 
activities in EC (Nakamura et al., 1996), thus suggesting that NK4 could inhibit HGF-
induced angiogenesis. Actually, NK4 potently inhibited the HGF-mediated proliferation of 
EC in vitro (Jiang et al., 1999b). Strikingly, NK4 also inhibited microvascular EC proliferation 
and migration, induced by other angiogenic factors, such as b-FGF and vascular endothelial  
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Fig. 2. Preparation of NK4 as an HGF-antagonist and its inhibitory effects on tumor invasion 
in vitro. (A) Preparation and structure of NK4. NK4 is generated via a cleavage of HGF 
between 478th Val and 479th Asn. (B) Inhibition of HGF-mediated MET tyrosine 
phosphorylation by NK4 in lung carcinoma cells. (C) Biological activity of NK4. Cancer cell 
invasion (upper chamber) is induced across a Matrigel layer when fibroblasts (FB) are 
placed on a lower chamber. In this co-culture system, NK4 inhibits FB-induced tumor cell 
invasion in a dose-dependent manner. 
growth factor (VEGF) (Fig. 3A) (Kuba et al., 2000). When a pellet containing b-FGF was 
implanted under the rabbit cornea, angiogenesis was rapidly induced. In this model, NK4 
inhibited b-FGF-induced angiogenesis (Fig. 3B). In vitro models of EC proliferation, HGF 
and VEGF phosphorylate MET and KDR/VEGF receptor, respectively, whereas NK4 
inhibits HGF-induced MET tyrosine phosphorylation, but not VEGF-induced KDR 
phosphorylation (Kuba et al., 2000). Nevertheless, NK4 inhibited the VEGF-mediated EC 
proliferation without modification of VEGF-mediated ERK1/2 (p44/42 mitogen-activated 
protein kinase) activation. These results suggest the presence of another mechanism 
whereby NK4 inhibits VEGF- and b-FGF-mediated angiogenesis. 
The fibronectin-integrin signal is essential for the spreading and proliferation of EC. Based 
on this background, we demonstrated that NK4-mediated growth arrest of EC is due to a 
loss of the fibronectin-integrin signal. Affinity purification with NK4-immobilized beads 
revealed that NK4 binds to perlecan (Sakai et al., 2009). Consistent with this result, NK4 was 
co-localized with perlecan in EC. Perlecan is a multi-domain heparan sulfate proteoglycan 
that interacts with basement membrane components such as fibronectin. Of interest, 
knockdown of perlecan expression by siRNA diminished the fibronectin assembly and EC 
spreading, indicating an essential role of fibronectin-perlecan interaction during EC 
movement. A recent report described that NK4-perlecan interaction suppressed the normal 
assembly of fibronectin by perlecan (Sakai et al., 2009). As a result, FAK activation became 
faint in EC after NK4 treatment. Under such a loss of fibronectin-integrin signaling by NK4, 
EC growth and motility were suppressed, even in the presence of b-FGF or VEGF. This is 
the reason why NK4 arrests b-FGF- or VEGF-mediated angiogenesis (Fig. 3C). 
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Fig. 3. Anti-angiogenic effects of NK4 via a perlecan-dependent mechanism. (A) NK4 
suppresses HGF-, b-FGF-, and VEGF-induced proliferation of EC in vitro (Kuba et al., 2000). 
(B) Inhibition of b-FGF-induced corneal neovascularization by NK4 treatment in rabbits. (C) 
Involvement of perlecan (PC) in NK4-mediated growth arrest of EC. Left: Cell surface PC is 
required for the binding of fibronectin and α5β1-integrin, leading to FAK phosphorylation 
and crosstalk of VEGF-VEGF receptor (KDR) signaling. Right: NK4 binds to PC, and then 
the binding of integrin to fibronectin is impaired. As a result, VEGF fails to elicit G1/S 
progression of EC in the presence of NK4 (Sakai et al., 2009). 
We have accumulated in vitro evidence showing that HGF-MET system may elicit cancer 
invasion via a paracrine loop of stroma-carcinoma interaction. This phenomenon is also 
demonstrated in vivo: anti-HGF antibody potently suppressed the tumor invasion in a 
mouse model of pancreas cancer (Tomiola et al., 2001). On the other hand, several 
investigators proposed, in the late-1990’s, a new concept that tumor angiogenesis inhibition 
leads to the arrest of cancer growth and metastasis (Yancopoulos et al., 1998). Inhibition of 
tumor angiogenesis leads to local hypoxia, and then apoptotic death of cancer cells is 
associated with the arrests of tumor growth and metastasis (i.e., cytostatic therapy). In this 
regard, NK4 also elicits an anti-angiogenic effect via perlecan-dependent mechanism. Thus, 
bi-functional properties of NK4 as an HGF antagonist and angiogenesis inhibitor raise a 
possibility that NK4 may prove therapeutic for cancer patients, as follows. 
5. Anti-cancer therapy using NK4 in animal models 
Carcinoma and sarcoma show malignant phenotypes prompted by a stroma-derived HGF-
MET signal at least in vitro. If NK4 could block MET signaling as an HGF-antagonist in vivo, 
supplemental therapy with NK4 would be a pathogenesis-based strategy to counteract 
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tumor invasion and metastasis. This hypothesis is widely demonstrated through extensive 
studies using tumor-bearing animals, as described below. 
5.1 First evidence of NK4 for inhibition of carcinoma progression in vivo 
HGF, or co-cultured fibroblasts, are known to induce invasion of gallbladder carcinoma cells 
(GB-b1) across Matri-gel basement membrane components (Li et al., 1998). NK4 
competitively inhibits the binding of HGF to MET on GB-d1 cells. As a result, NK4 
diminishes HGF-induced, or fibroblast-induced, motogenic activities (Date et al., 1998), thus 
suggesting that stroma-derived HGF is a key conductor for provoking tumor invasion. Such 
an important role of HGF was also demonstrated in vivo. Subcutaneous inoculations of 
human gallbladder carcinoma GB-d1 cells in nude mice allow for primary tumor growth 
and invasion to adjacent muscular tissues. Using this conceptual model, we provided the 
first evidence of NK4 as an anti-tumor drug (Date et al., 1998). Recombinant NK4 has 
inhibited the growth and muscular invasion in a mouse model of gallbladder carcinoma. 
Consistent with tumor growth arrest, apoptotic change becomes evident during NK4 
injections. Since HGF has an anti-apoptotic effect on cancer cells (Zeng et al., 2002), reverse 
of HGF-induced protection by NK4 may be one of the mechanisms whereby carcinoma 
growth can be suppressed during NK4 supplemental therapy. 
5.2 Inhibition of tumor angiogenesis by NK4 treatment 
In a culture of EC, NK4 produces anti-angiogenetic effects via a MET-independent pathway 
(Kuba et al., 2000; Nakabayashi et al., 2003). These effects are also observed in animal models 
of malignant tumors: administration of recombinant NK4 suppressed primary tumor 
growth, metastasis of Lewis lung carcinoma, and Jyg-MC(A) mammary carcinoma 
implanted into mice (Kuba et al., 2000), although neither HGF nor NK4 affected proliferation 
and survival of these tumor cells in vitro. NK4 treatment resulted in a remarkable decrease 
in microvessel density and an increase in apoptotic tumor cells in primary tumors, 
suggesting that the inhibition of tumor growth by NK4 may be achieved by the suppression 
of tumor angiogenesis (Kuba et al., 2000). The anti-angiogenic effects of NK4 are widely 
demonstrated in various types of cancers [see our review articles (Matsumoto & Nakamura, 
2005; Matsumoto et al., 2008a,b)]. Because the inhibition of angiogenesis by NK4 leads to 
tumor hypoxia, hypoxia-primed apoptosis may contribute to a reduction in tumor size 
during NK4 supplemental therapy. 
5.3 Delayed NK4 therapy for attenuation of end-stage pancreas carcinoma 
Anti-tumor effect of NK4 is also observed in a mouse model of advanced pancreas 
carcinoma (Tomioka et al., 2001). When NK4 treatment was initiated on day 10, a time when 
cancer cells were already invading surrounding tissues, NK4 potently inhibited the tumor 
growth, peritoneal dissemination, and ascites accumulation at 4 weeks after the inoculation. 
Such an anti-tumor effects of NK4 correlated with decreased vessel density in pancreatic 
tumors. In an end-stage of pancreas cancer, NK4 inhibited the malignant phenotypes, such 
as peritoneal dissemination, invasion of cancer cells into the peritoneal walls and ascites 
accumulation (Tomioka et al., 2001). As a result, NK4 prolonged the survival time of mice at 
an end-stage of cancer (Fig. 4). Because effective systemic therapy for pancreatic cancer is 
currently not available, and diagnosing pancreatic cancer in its early stages is difficult, the 
highly invasive and metastatic behaviors of pancreatic cancer lead to difficulty in attaining a  
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Fig. 4. Anti-tumor effects of NK4 on advanced pancreas cancer in mice. (A) Schedules for 
NK4 treatment of mice with pancreatic cancer. NK4 was injected into mice between 3 and 28 
days after the inoculation of human pancreatic cancer cells (SUIT-2). (B) Inhibition of 
primary tumor growth by NK4. Photographs show appearance of the primary pancreatic 
cancer. (C) Histological analysis of the effect of NK4-treatment on tumor angiogenesis (left) 
and apoptosis (right). NK4-treatment reduced the number of vessel numbers, while 
apoptotic death of cancers was enhanced by NK4. (D) Inhibitory effects of NK4 on 
peritoneal metastasis. Left: Typical macroscopic findings. Middle: Changes in the number of 
metstatic nodules. Right: Changes in the ascite volumes. (E) Prolonged survival of tumor-
bearing mice treated with NK4. 
long-term survival and a recurrence-free status. Targeting tumor angiogenesis and blockade 
of HGF-mediated invasion of cancer cells may prove to be potential therapy for patients 
with pancreatic cancer.  
5.4 Therapy combining NK4 with other treatments 
Anti-cancer chemotherapy is widely used for the suppression of malignant tumors with or 
without surgical treatment. Therapy regimens that combine anti-cancer chemo drugs and 
NK4 enhance their anti-tumor effect (Matsumoto et al., 2011). Irradiation therapy often 
enhances cancer metastasis, especially in cases of pancreatic carcinoma, and this is 
associated with the irradiation-induced up-regulation of HGF in fibroblasts (Qian et al., 
2003; Ohuchida et al., 2004). Thus, NK4 may overcome these irradiation-associated side 
effects. 
Epidermal growth factor receptor (EGFR) kinase inhibitors, such as Gefitinib, are used to 
treat non-small cell lung cancers that have activating mutations in the EGFR gene, but most 
of these tumors become resistant to EGFR-kinase inhibitors due to enhancement of HGF-
MET signals (Engelman et al., 2007; Yano et al., 2008; Okamoto et al., 2010). Thus, NK4 
treatment may reverse HGF-induced resistance to Gefitinib. 
www.intechopen.com
Endocrine Delivery System of NK4, an HGF-Antagonist and  
Anti-Angiogenic Regulator, for Inhibitions of Tumor Growth, Invasion and Metastasis 
 
129 
Recently, it was demonstrated that NK4-mediated tumor regression depends on the 
infiltration of cytotoxic T lymphocytes (Kubota et al., 2009b). Importantly, depletion of CD8+ 
cells markedly abrogated the anti-tumor activity of NK4 in a mouse model of colon cancer. 
NK4 enhances immune responses in dendritic cells in vitro. Thus, NK4 may also have utility 
for anti-tumor immunotherapy. 
There is now ample evidence that NK4 is useful for the inhibition of growth, invasion and 
metastasis in various types of tumors, such as gastric carcinoma (Hirao et al., 2002), pancreas 
cancer (Tomioka et al., 2001), prostate cancer (Davies et al., 2003), multiple myeloma (Du et 
al., 2007) and melanoma (Kishi et al., 2009) (Table-1). These results support our hypothesis 
that HGF is a key determinant of tumor malignancy (Matsumoto et al., 1996b). 
 
Tumor diseases NK4 therapy     Outcome Literature 
(Cell lines and treatment) 
 
 A. Digestive system: 
  Gastric carcinoma Adeno-NK4, ip  Inhibitions of growth Ueda K et al., 
    (TMK1 cells,   and metastasis,  Eur J Cancer  
     ip, Mouse)   Anti-angiogenesis, 40: 2135-2142 
   Reduced ascites  (2004) 
 
  Hepatic carcinoma Adeno-NK4, iv Inhibitions of growth, Son G et al., 
    (HUH7 cells,  Anti-angiogenesis, J Hepatol 45: 
     portal vein, Mouse)  Prolonged survival 688-695 (2006) 
 
  Gallbladder cancer NK4, sc   Inhibitions of growth Date K et al., 
    (GB-d1 cells,   and invasion  Oncogene 17: 
     sc, Mouse)     3045-354 (1998) 
 
  Pancreatic carcinoma r-NK4, ip   Inhibitions of growth, Tomioka Det al., 
    (SUIT-2 cells,  invasion and metastasis, Cancer Res 61:  
     intra-pancreas,  Anti-angiogenesis, 7518-7524 
     Mouse)  Reduced ascites, (2001) 
  Prolonged survival 
 
  Colon carcinoma NK4 cDNA, Inhibitions of growth, Wen J et al., 
    (MC-38 cells, bolus iv   invasion and metastasis, Cancer Gen Ther 
     intra-spleen, (hydrodynamics) Anti-angiogenesis, 11: 419-430 
     Mouse)   Prolonged survival (2004) 
 
 B. Respiratory system: 
  Lung carcinoma r-NK4, sc   Inhibitions of growth Kuba K et al., 
    (Lewis carcinoma,   and metastasis,  Cancer Res 60: 
     sc, Mouse)   Anti-angiogenesis, 6737-6743 
   Enhanced apoptosis (2000) 
 
  Lung carcinoma Adeno-NK4, Inhibition of growth, Maemondo M 
    (A549 cells, intra-tumor  Anti-angiogenesis et al., Mol Ther 5: 
     sc, Mouse) or ip    177-185 (2002) 
 
  Mesothelioma Adeno-NK4, Inhibition of growth, Suzuki Y et al., 
    (EHMES-10 cells, intra-tumor  Enhanced apoptosis, Int J Cancer 127:  
     sc, Mouse)   Anti-angiogenesis 1948-1957  
     (2010) 
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 C. Reproductive system: 
  Prostate carcinoma r-NK4, sc   Inhibition of growth, Davies G et al., 
    (PC-3 cells,  (osmotic pump) Anti-angiogenesis Int J Cancer 106: 
     sc, Mouse)     348-354 (2003) 
 
  Ovarian carcinoma NK4 gene,  Inhibition of metastasis, Saga Y et al., 
    (HRA cells, Stable   Prolonged survival Gene Ther 8:  
     ip, Mouse) transfection   1450-1455 (2001) 
 
 D. Hematopoietic system: 
  Lymphoma Adeno-NK4, Inhibition of growth, Kikuchi T et al., 
    (E.G7-OVA cells, intra-tumor  Anti-angiogenesis, Blood 100:  
     sc, Mouse) (with DC)  Induction of CTL 3950-3959 
     (2003) 
 
  Multiple myeloma Adeno-NK4, im  Inhibition of growth, Du W et al., 
    (KMS11/34 cells,   Anti-angiogenesis, Blood 109: 
     sc, Mouse)   Enhanced apoptosis 3042-3049 
     (2007) 
 
 E. Other organ or tissues: 
  Melanoma Adeno-NK4, iv  Inhibitions of growth Kishi Y et al., 
    (B16F10 cells,   and metastasis,  Cancer Sci 100: 
     sc, Mouse)   Anti-angiogenesis 1351-1358 
     (2009) 
 
  Glioblastoma r-NK4,  Inhibition of growth, Brockmann MA 
    (U-87 MG cells, intra-tumor  Anti-angiogenesis, et al., Clin Cancer 
     Intra-brain, Mouse)   Enhanced apoptosis Res 9: 
     4578-4585 
     (2003) 
 
  Breast carcinoma r-NK4, sc   Inhibition of growth, Martin TA et al., 
    (MDAMB231 cells,   Anti-angiogenesis Carcinogenesis 
     sc, Mouse)     24: 1317-1323 
          (2003) 
 
Adeno-NK4, adenoviral vector carrying NK4 cDNA; r-NK4, recombinant NK4 protein; sc, 
subcutaneous; iv, intravenous; ip, intraperitoneal; im, intramuscular; DC, dendritic cells; and CTL, 
cytotoxic T lymphocytes. 
Table 1. Representative studies to show therapeutic effects of NK4 on distinct types of 
tumors in animal models 
6. Hydodynamics-based NK4 gene therapy for colon cancer inhibition 
Hydrodynamic delivery has emerged as the simplest and effective method for intracellular 
delivery of subjective genes in rodents; this process requires no special equipment. The 
system employs a physical force generated by the rapid injection of a large volume of 
solution into a blood vessel to enhance the permeability of endothelium and the plasma 
membrane of the parenchyma cells, such as hepatocytes, to facilitate a delivery of the 
substance into cells (Bonamassa et al., 2011). Using this technique in mice, we established an 
endocrine delivery system for NK4 that leads to an inhibition of the malignant behavior of 
cancers, as follows. 
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6.1 NK4 supplementation system via hydrodynamic gene delivery in mice 
Numerous clinical studies have indicated the apparent increases in serum HGF levels in 
patients during the progression of cancers (Wu et al., 1998; Osada et al., 2008). It is likely that 
HGF in blood protects cancer cell suspension from anoikis-like cell death (Zeng et al., 2002). 
Thus, we predict that over-production of NK4 in blood would overcome the HGF-mediated 
metastatic events seen in blood flow (and possibly in local sites). Hydrodynamic-based gene 
delivery is known to achieve an efficient expression of exogenous genes predominantly in 
the liver but much lesser in the kidney and spleen (Suda et al., 2007). Based on this 
background, we established a method for the induction and maintenance of higher levels of 
NK4 in blood through repeated injections of NK4 cDNA-containing plasmid. 
For hydrodynamic-based gene delivery, 5 microgram of plasmid DNA (pCAGGS-NK4), or 
pCAGGS-empty (as a control), in saline was injected within 5 seconds into tail veins of mice 
at 2.4 ml per 30g body weight (Wen et al., 2004; 2007). As a result, exogenous NK4 was 
detected, and plasma NK4 reached a mean value of 49.5 ng/ml 24 hours post-bolus injection 
and decreased to 15.4 ng/ml on day 3. Following the second and third injections, the plasma 
NK4 level again reached approximately 70 and 130 ng/ml on days 8 and 15, respectively. 
Thus, plasma NK4 levels increased following additional administration of the expression 
plasmid, and were maintained at levels of > 8 ng/ml during 3 weeks post-treatment (Fig. 5). 
 
 
Fig. 5. Hydrodynamics-mediated NK4 delivery system in mice. (A) An experimental 
protocol of NK4 gene administration. Five microgram of pCAGGS-NK4 was administered 
intravenously into mice on day 0, 7 and 14. (B) Changes in plasma NK4 levels following 
repetitive administration of expression plasmid for NK4. Arrows mean the time of plasmid 
administration. See reference (Wen et al., 2007) for further information. 
6.2 Inhibition of colon cancer metastasis by NK4 gene delivery 
Colon cancer is one of the most common cancers in the world, with a high propensity to 
metastasize: 30-40% of patients have metastatic disease at the initial diagnosis. The liver is 
the most frequent site of metastasis, and hepatic failure is a lethal event during colon cancer. 
Thus, direct inhibition of the dissociation, spreading and invasion of cancer cells is expected 
to become efficient treatment. With regard to this, HGF stimulates the invasion of MC-38 
mouse colon cancer cells across MatriGel (Parr et al., 2000), which is composed of laminin 
and other matrices and mimics the basement membrane in vivo. In this model, NK4 has 
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inhibited the HGF-mediated migration of MC-38 cells in a culture model of colon cancer 
invasion. This anti-invasive effect of NK4, obtained by in vitro studies, is demonstrated in 
vivo in the following two studies. 
An hepatic metastatic model was prepared by the injection of mouse MC-38 cells into the 
spleen. During the progression of colon cancer in hepatic tissues, HGF was over-produced 
by hepatic sinusoidal cells, while MET tyrosine phosphorylation became evident, 
particularly around the front lines of invasive zones. Supplementation of NK4 in blood and 
livers via a single injection of NK4-cDNA containing plasmid (pCAGGS-NK4) resulted in 
the loss of MET tyrosine phosphorylation (Fig. 6). Under such a MET-inactivated condition 
by NK4 treatment, hepatic invasion by colon carcinoma was strongly inhibited (Wen et al., 
2004). 
 
 
Fig. 6. Successful outcome of hydrodynamics-based NK4 gene therapy in a mouse model of 
colon cancer. The hepatic invasion model is prepared by intra-splenic inoculation of MC-38 
colon carcinoma in mice. In the control group, invasion of carcinoma cells into neighboring 
hepatic areas becomes evident, along with an induction of MET tyrosine phosphorylation 
(p-MET) and an increase in vessel numbers. In contrast, NK4 suppresses tumor invasion by 
inhibiting MET tyrosine phosphorylation and reducing angiogenesis. As a result, NK4 gene 
therapy prolongs the survival of these mice (Wen et al., 2004). 
Repeated administrations of NK4-containing plasmid DNA also inhibited the malignant 
behaviors of colon carcinoma (Wen et al., 2007). Actually, NK4 repetitive gene therapy 
potently inhibited the muscular invasion of MC-38 carcinoma cells. Furthermore, 
angiogenesis in the colon cancer was markedly suppressed by NK4 repetitive therapy, along 
with an increase in tumor apoptosis. Overall, the number of hepatic metastatic nodules was 
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dramatically decreased by the repeated injections of NK4-cDNA containing plasmid. This 
study provides an anti-tumor model where NK4 is supplemented via a hydrpdynamics-
based gene therapy (Wen et al., 2007). 
Recently, hydrodynamic gene delivery using a rapid injection of a relatively large volume of 
DNA solution has facilitated experimental gene therapy studies, particularly in rodents 
(Suda et al., 2007). This method is superior to the existing delivery systems because of its 
simplicity, efficiency, and versatility. Hydrodynamic gene delivery is also useful for 
supplementation of HGF, an intrinsic repair factor, for the inhibition of, or recovery from, 
intractable organ diseases, such as acute renal failure (Dai et al., 2002) or pulmonary airway 
hyper-responsiveness during asthma (Okunishi et al., 2005). In these experiments, plasma 
HGF levels were sustained within a pharmacological range (3-30 ng/ml). Wide success in 
applying hydrodynamic principles to delivery of NK4- or HGF-related DNA, RNA, 
proteins, and synthetic compounds, into the cells in various tissues of small animals, has 
inspired the recent attempts at establishing a hydrodynamic procedure for clinical use. 
7. Summary and perspective 
NK4-related studies provided a proof-of-concept that MET signaling from stroma-derived 
HGF plays a pivotal role in eliciting tumor invasion and metastasis (Matsumoto & 
Nakamura., 2005; Nakamura et al., 2010). Human genetic studies also strengthened the 
important role of MET activation for tumor malignancy. There is now ample evidence to 
demonstrate the role of MET mutations in tumor malignancy (Lengyel et al., 2007; 
Matsumoto et al., 2008a,b; Pao et al., 2011). Of interest, mutation of the von-Hippel-Lindau 
(VHL) gene leads to renal clear cell carcinoma through constitutive MET tyrosine 
phosphorylation (Nakaigawa et al., 2006), hence suggesting a critical role of wild-type VHL 
in inhibiting MET over-activation as a negative regulator. 
During the progression of malignant tumors, soluble MET is producible by carcinoma cells 
through an ectodomain shedding cascade (Wader et al., 2011). Soluble MET inhibits the 
HGF-MET complex and signaling transduction. Thus, MET shedding system is considered 
as a self-defense response that minimizes tumor metastasis. Likewise, an NK4-like fragment 
of the HGF α-chain can be secreted from human breast carcinoma, which inhibits MET 
tyrosine phosphorylation (Wright et al., 2009). Thus, “endogenous” soluble MET and NK4-
like variant appear to reduce HGF-MET signaling and delay tumor progression, but this 
response is insufficient, allowing for tumor metastasis. Thus, supplemental therapy with 
NK4 is a reasonable strategy to completely block tumor metastasis. 
The hope is that angiogenesis inhibition might control tumor metastasis (Yancopoulos et al., 
1998). However, long-term use of angiogenesis inhibitors, such as VEGF inhibitor, results in 
hypoxia-resistance (Fischer et al., 2007), possibly due to hypoxia-induced MET up-regulation 
by cancer (Bottaro & Liotta, 2003). NK4 is an angiogenesis inhibitor with the ability to inhibit 
MET activation, and discovery of this fragment opened up a new avenue for the 
development of freeze-and-dormancy therapy (Fig. 7). Thus, NK4 is now defined as 
“Malignostatin”. In addition to NK4, several anti-metastatic drugs have been proposed, 
with a major focus on small molecules that inhibit the tyrosine kinase activity of MET; 
ribozyme; small-interfering RNA; anti-HGF antibodies; soluble MET; and HGF-variant 
decoys (Jiang et al., 2005; Benvenuti & Comoglio, 2007; Eder et al., 2009; Underiner et al., 
2010; Cecchi et al., 2010). HGF-MET targeting research will shed more light on cancer 
biology, pathology and new technologies to overcome host death due to cancer metastasis. 
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Fig. 7. Freeze-and-dormancy therapy of malignant tumors by NK4/malignostatin. NK4 
blocks tumor invasion and metastasis through an inhibition of HGF-MET signals as an 
HGF-antagonist. Furthermore, NK4 inhibits tumor angiogenesis via a perlecan-dependent 
mechanism. Such a dual function of NK4 contributes to “freeze” and “dormancy” anti-
cancer therapy. 
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